Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers

Background The effect of longer-term use of bone-modifying agent (BMA) on symptomatic skeletal event (SSE) rates in patients with bone metastases remains unclear. This retrospective study of a cohort of patients in a randomized controlled trial evaluated SSEs in patients receiving BMAs at a single c...

Full description

Saved in:
Bibliographic Details
Published in:Supportive care in cancer 2022-05, Vol.30 (5), p.3977-3984
Main Authors: Alzahrani, Mashari, Stober, Carol, Liu, Michelle, Awan, Arif, Ng, Terry L., Pond, Gregory, Alshamsan, Bader, Vandermeer, Lisa, Clemons, Mark
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Bone cancer
Bone density
Bone Neoplasms - drug therapy
Bone Neoplasms - secondary
Breast cancer
Cancer patients
Castration
Denosumab
Diagnosis
Disodium pamidronate
Drug therapy
Humans
Male
Medical research
Medicine
Medicine & Public Health
Medicine, Experimental
Metastasis
Middle Aged
Monoclonal antibodies
Nursing
Nursing Research
Oncology
Original Article
Pain Medicine
Prostate cancer
Prostatic Neoplasms, Castration-Resistant - drug therapy
Prostatic Neoplasms, Castration-Resistant - pathology
Rehabilitation Medicine
Retrospective Studies
Risk factors
Side effects
Zoledronic Acid - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The effect of longer-term use of bone-modifying agent (BMA) on symptomatic skeletal event (SSE) rates in patients with bone metastases remains unclear. This retrospective study of a cohort of patients in a randomized controlled trial evaluated SSEs in patients receiving BMAs at a single cancer center. Methods Data from patients with metastatic breast and castration-resistant prostate cancer (CRPC) were interrogated to evaluate the effects of longer-term use of BMAs on incidence, type, and risk factors for SSEs. Results Of 162 patients, 109 (67%) had breast cancer (BC) and 53 (33%) CRPC. Median age at diagnosis of bone metastases was 61.9 years (range 27.5–97.2) for BC patients and 72.1 (range 37.0–92.2) for CRPC patients. Median duration of BMA use was 2.3 years (range 0.1–9.9 years) for BC and 3.8 years (range 1.5–9.4) for CRPC patients. The initial BMAs in BC patients were pamidronate (46.8%), denosumab (31.2%), and zoledronate (22%). All CRPC patients received denosumab. During follow-up, 59% of BC and 75% of CRPC patients had at least one SSE. The number of patients experiencing ≥ 1 SSE per year was higher in the first year after bone metastasis diagnosis (63/162; 38.9%) compared with that in the second (26/149; 17.5%) and third years (30/123; 24.4%). Neither age, visceral disease, multiple bone metastases, nor biological markers for BC had a significant impact on time to first SSE. Conclusions The risk for SSEs was greatest in the first year after diagnosis of bone metastasis. Studies evaluating de-escalation and even stopping of BMAs with longer-term use may therefore be warranted.
ISSN:0941-4355
1433-7339
DOI:10.1007/s00520-021-06714-8